Drug interactions of Avapritinib

Effects of Other Drugs on Avapritinib (AYVAKIT)

Strong and Moderate CYP3A Inhibitors

Concomitant use of avapritinib (AYVAKIT) with strong or moderate CYP3A inhibitors increases the plasma concentration of avapritinib, which may raise the incidence and severity of adverse reactions to avapritinib (AYVAKIT). Concomitant use of avapritinib (AYVAKIT) with strong or moderate CYP3A inhibitors should be avoided. If concomitant use of avapritinib (AYVAKIT) with a moderate CYP3A inhibitor cannot be avoided, the dose of avapritinib (AYVAKIT) needs to be reduced.

Strong and Moderate CYP3A Inducers

Concomitant use of avapritinib (AYVAKIT) with strong or moderate CYP3A inducers decreases the plasma concentration of avapritinib [see Clinical Pharmacology (12.3)], which may reduce the efficacy of avapritinib (AYVAKIT). Concomitant use of avapritinib (AYVAKIT) with strong or moderate CYP3A inducers should be avoided.

Effects of Avapritinib (AYVAKIT) on Other Drugs

Concomitant use of avapritinib (AYVAKIT) with contraceptives containing ethinylestradiol may increase the exposure to ethinylestradiol, which may raise the risk of adverse reactions associated with ethinylestradiol.

If patients cannot use or tolerate effective non-hormonal contraceptives, or cannot use effective hormonal contraceptives without estrogen, formulations containing 20 micrograms or less of ethinylestradiol should be used, unless a higher dose is necessary.

FDA，2024.11